Phase I : Trial Evaluating the Safety of Preoperative Gemcitabine/nab-Paclitaxel With Concurrent Radiation Therapy for Borderline Resectable Pancreatic Cancer
Mené au Japon sur 38 patients atteints d'un cancer du pancréas à la limite de la résécabilité, cet essai de phase I évalue la toxicité d'une chimiothérapie pré-opératoire par gemcitabine/nab-paclitaxel en combinaison avec une radiothérapie concomitante et détermine la dose recommandée pour chacun des agents anticancéreux
Objectives : The objectives of this study were to assess the feasibility of preoperative gemcitabine/nab-paclitaxel–based chemoradiation therapy (CRT) for patients with borderline resectable pancreatic cancer (BRPC), which consists of induction chemotherapy and subsequent CRT, and to determine the recommended dose (RD) of gemcitabine/nab-paclitaxel with concurrent radiation therapy in a phase I trial. Methods : Patients with BRPC received gemcitabine (1000 mg/m2)/nab-paclitaxel (125 mg/m2) on days 1, 8, and 15 during each 4-week cycle, which was repeated for 2 cycles as induction chemotherapy. After induction chemotherapy, the patients received gemcitabine/nab-paclitaxel with concurrent radiation therapy. During CRT, the patients were scheduled to receive gemcitabine/nab-paclitaxel at 7 dose levels using a standard 3 + 3 dose escalation scheme. Radiation therapy was concurrently delivered at a total dose of 60 Gy. Results : Thirty-eight patients initiated induction gemcitabine/nab-paclitaxel. Among these patients, 30 received subsequent gemcitabine/nab-paclitaxel–based CRT. The RD was determined to be level 5 (gemcitabine, 800 mg/m2; nab-paclitaxel, 100 mg/m2). The dose-limiting toxicities included hematologic toxicity, infection, febrile neutropenia, and peripheral neuropathy. Twenty-four of 30 patients underwent pancreatectomy, and the R0 resection rate was 96%. Conclusions : The RD of gemcitabine/nab-paclitaxel–based CRT after induction gemcitabine/nab-paclitaxel for patients with BRPC was 800 and 100 mg/m2, respectively.